Top

Published in:

Open Access 01-12-2022 | Chloroquin | Research article

Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles

Authors: Annie R. A. McDougall, Roxanne Hastie, Maya Goldstein, Andrew Tuttle, Stephen Tong, Anne Ammerdorffer, A. Metin Gülmezoglu, Joshua P. Vogel

Published in: BMC Medicine | Issue 1/2022

Abstract

Background

The Accelerating Innovation for Mothers (AIM) project established a database of candidate medicines in research and development (R&D) between 2000 and 2021 for five pregnancy-related conditions, including pre-eclampsia. In parallel, we published target product profiles (TPPs) that describe optimal characteristics of medicines for use in preventing/treating pre-eclampsia. The study objective was to use systematic double screening and extraction to identify all candidate medicines being investigated for pre-eclampsia prevention/treatment and rank their potential based on the TPPs.

Methods

Adis Insight, Pharmaprojects, WHO international clinical trials registry platform (ICTRP), PubMed and grant databases were searched (Jan–May 2021). The AIM database was screened for all candidates being investigated for pre-eclampsia. Candidates in clinical development were evaluated against nine prespecified criteria from TPPs identified as key for wide-scale implementation, and classified as high, medium or low potential based on matching to the TPPs. Preclinical candidates were categorised by product type, archetype and medicine subclass.

Results

The AIM database identified 153 candidates for pre-eclampsia. Of the 87 candidates in clinical development, seven were classified as high potential (prevention: esomeprazole, l-arginine, chloroquine, vitamin D and metformin; treatment: sulfasalazine and metformin) and eight as medium potential (prevention: probiotic lactobacilli, dalteparin, selenium and omega-3 fatty acid; treatment: sulforaphane, pravastatin, rosuvastatin and vitamin B3). Sixty-six candidates were in preclinical development, the most common being amino acid/peptides, siRNA-based medicines and polyphenols.

Conclusions

This is a novel, evidence-informed approach to identifying promising candidates for pre-eclampsia prevention and treatment — a vital step in stimulating R&D of new medicines for pre-eclampsia suitable for real-world implementation.

Available only for authorised users

Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7.CrossRef

Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33.CrossRef

Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–7.CrossRef

WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva; 2011.

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094–112.CrossRef

WHO recommendations on antiplatelet agents for prevention of pre-eclampsia (2021 update). Accepted for publication 2021.

WHO. WHO recommendation: calcium supplementation during pregnancy for prevention of pre-eclampsia and its complications. Geneva: World Health Organisation; 2018.

Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med. 2008;5(1):e22.CrossRef

Chappell LC, David AL. Improving the pipeline for developing and testing pharmacological treatments in pregnancy. PLoS Med. 2016;13(11):e1002161.CrossRef

10.

WHO, UNICEF, UNFPA, World Bank Group, UN. Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population Division. Geneva: WHO; 2019.

11.

AIM. Medicines for pregnancy-specific conditions: research, development and market analysis. Geneva; 2020.

12.

Footman K, Chersich M, Blaauw D, Campbell OM, Dhana A, Kavanagh J, et al. A systematic mapping of funders of maternal health intervention research 2000-2012. Glob Health. 2014;10:72.CrossRef

13.

Concept Foundation. Medicines for pregnancy specific conditions: research, development and market analysis 2021. Available from: https://www.conceptfoundation.org/global-news/medicines-for-pregnancy-specific-conditions-research-development-and-market-analysis/.

14.

Concept Foundation. Accelerating innovation for mothers: target product profiles Geneva. Switzerland: Concept Foundation; 2021. Available from: https://www.conceptfoundation.org/accelerating-innovation-for-mothers/target-product-profiles/

15.

WHO Target Product Profiles, Preferred product characteristics, and target regimen profiles: standard procedure. Geneva, Switzerland.

16.

Lewin SR, Attoye T, Bansbach C, Doehle B, Dube K, Dybul M, et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2021;8(1):e42–50.CrossRef

17.

Murtagh M, Blondeel K, Peeling RW, Kiarie J, Toskin I. The relevance of target product profiles for manufacturers, experiences from the World Health Organization initiative for point-of-care testing for sexually transmitted infections. Arch Public Health. 2021;79(1):187.CrossRef

18.

Pelle KG, Rambaud-Althaus C, D'Acremont V, Moran G, Sampath R, Katz Z, et al. Electronic clinical decision support algorithms incorporating point-of-care diagnostic tests in low-resource settings: a target product profile. BMJ Glob Health. 2020;5(2):e002067.CrossRef

19.

WHO. Target product profiles for needed antibacterial agents: enteric fever, gonorrhoea, neonatal sepsis, urinary tract infections and meeting report. Geneva: World Health Organisation; 2020. Contract No.: Licence: CC BY-NC-SA 3.0 IGO.

20.

Concept Foundation. Accelerating innovation for mothers: pipeline candidates Geneva, Switzerland: Concept Foundation; 2021. Available from: https://www.conceptfoundation.org/accelerating-innovation-for-mothers/aim-pipeline-candidates/.

21.

McDougall AR, Goldstein M, Tuttle A, Ammerdorffer A, Rushwan S, Hastie R, et al. Innovations in the prevention and treatment of postpartum hemorrhage: analysis of a novel medicines development pipeline database. Int J Gynecol Obstet. 2022;158(Suppl 1):31–9.CrossRef

22.

Dorniak-Wall T, Grivell RM, Dekker GA, Hague W, Dodd JM. The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomised trials. J Hum Hypertens. 2014;28(4):230–5.CrossRef

23.

Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011;342:d2901.CrossRef

24.

Hyett J. ACTRN12618001755224 - Can esomeprazole improve outcomes in women at high risk of pre-eclampsia? A phase II placebo-controlled randomised multi-centre clinical trial. The ESPRESSO Study. Canberra; Australia: ANZCTR; 2018. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375343.

25.

Cochrane Central Register of Controlled Trials: A Prospective, Pre-ecLampsia/Eclampsia Prevention IntervEntion - ACTRN12618000690257: Cochrane Library; 2018. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01897800/full.

26.

Farouk H. Esomeprazole for the prevention of preeclampsia: NIH: US National Library of Medicine; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03717740.

27.

Palacios C, Kostiuk LK, Pena-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2019;7:CD008873.PubMed

28.

Retraction of vitamin D supplementation affects serum high-sensitivity C-reactive protein, insulin resistance, and biomarkers of oxidative stress in pregnant women. J Nutr 2013;143(9):1432–38. The Journal of nutrition. 2021;151(5):1359.

29.

Hu KL, Zhang CX, Chen P, Zhang D, Hunt S. Vitamin D levels in early and middle pregnancy and preeclampsia, a systematic review and meta-analysis. Nutrients. 2022;14(5).

30.

Bakouei F, Delavar MA, Mashayekh-Amiri S, Esmailzadeh S, Taheri Z. Efficacy of n-3 fatty acids supplementation on the prevention of pregnancy induced-hypertension or preeclampsia: a systematic review and meta-analysis. Taiwan J Obstet Gynecol. 2020;59(1):8–15.CrossRef

31.

Makrides M, Best K, Yelland L, McPhee A, Zhou S, Quinlivan J, et al. A randomized trial of prenatal n-3 fatty acid supplementation and preterm delivery. N Engl J Med. 2019;381(11):1035–45.CrossRef

32.

Rayman MP, Bath SC, Westaway J, Williams P, Mao J, Vanderlelie JJ, et al. Selenium status in U.K. pregnant women and its relationship with hypertensive conditions of pregnancy. Br J Nutr. 2015;113(2):249–58.CrossRef

33.

Tara F, Maamouri G, Rayman MP, Ghayour-Mobarhan M, Sahebkar A, Yazarlu O, et al. Selenium supplementation and the incidence of preeclampsia in pregnant Iranian women: a randomized, double-blind, placebo-controlled pilot trial. Taiwan J Obstet Gynecol. 2010;49(2):181–7.CrossRef

34.

Lane C, A. ClinicalTrials.gov: vascular inflammation and anti-inflammatory supplements after adverse pregnancy outcomes (VIA): NIH; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04633551.

35.

Jacobsson B. ClinicalTrials.gov: pregnancy complications - a probiotic interventional study: NIH; 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02693041?term=NCT02693041&draw=2&rank=1.

36.

Mastrolia SA, Novack L, Thachil J, Rabinovich A, Pikovsky O, Klaitman V, et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):868–78.CrossRef

37.

Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thrombosis Haemostasis. 2009;7(1):58–64.CrossRef

38.

Duan J, Ma D, Wen X, Guo Q, Gao J, Zhang G, et al. Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: a meta-analysis. Lupus. 2021;30(7):1163–74.CrossRef

39.

Mohammed AM. ClinincalTrials.gov: hydroxychloroquine in prevention of preeclampsia: NIH; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04755322.

40.

Alqudah A, McKinley MC, McNally R, Graham U, Watson CJ, Lyons TJ, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med. 2018;35(2):160–72.CrossRef

41.

Mohamed M. Prevention of pre-eclampsia using metformin: a randomized control trial (PREMET): NIH: US National Library of Medicine; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04855513.

42.

Langston-Cox AG, Marshall SA, Palmer KR, Wallace EM. Prolong: a double-blind randomised placebo-controlled trial of broccoli sprout extract in women with early onset preeclampsia. A clinical trial protocol. BMJ Open. 2019;9(10):e027493.PubMedPubMedCentral

43.

Ahmed A, Williams DJ, Cheed V, Middleton LJ, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2020;127(4):478–88.CrossRef

44.

Cluver CA, Hiscock R, Decloedt EH, Hall DR, Schell S, Mol BW, et al. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021;374:n2103.CrossRef

45.

Beharier O. Rosuvastatin in order to induce preeclampsia resolution in severe PET up to 48 hours following delivery 2014. Available from: https://clinicaltrials.gov/ct2/show/NCT02314286.

46.

Mansour S. Effect of rosuvastatin on the clinical features of preeclampsia 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04303806.

47.

Boggess K. Study of nicotinamide in early onset preeclampsia 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT03419364.

48.

Brownfoot B. ANZCTR12617000226303: pharmacokinetics of sulfasalazine for the treatment of preterm preeclampsia: an early phase clinical trial 2017. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371611.

49.

Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019;15(5):275–89.CrossRef

50.

Tong S, Kaitu'u-Lino TJ, Hastie R, Brownfoot F, Cluver C, Hannan N. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol. 2020.

51.

de Alwis N, Binder NK, Beard S, Kaitu'u-Lino TJ, Tong S, Brownfoot F, et al. Novel approaches to combat preeclampsia: from new drugs to innovative delivery. Placenta. 2020;102:10–6.CrossRef

52.

Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.CrossRef

53.

Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Translational Medicine. Communications. 2019;4(18).

54.

Hahn S. Preeclampsia - will orphan drug status facilitate innovative biological therapies? Front Surg. 2015;2:7.CrossRef

55.

Spencer R, Rossi C, Lees M, Peebles D, Brocklehurst P, Martin J, et al. Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe. BJOG. 2019;126(9):1157–67.CrossRef

56.

Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gulmezoglu A, Widmer M. Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature. BJOG. 2016;123(13):2076–86.CrossRef

57.

Ormesher L, Myers JE, Chmiel C, Wareing M, Greenwood SL, Tropea T, et al. Effects of dietary nitrate supplementation, from beetroot juice, on blood pressure in hypertensive pregnant women: a randomised, double-blind, placebo-controlled feasibility trial. Nitric Oxide. 2018;80:37–44.CrossRef

58.

Valensise H, Vasapollo B, Novelli GP, Giorgi G, Verallo P, Galante A, et al. Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. Ultrasound Obstet Gynecol. 2008;31(1):55–64.CrossRef

Title: Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles
Authors: Annie R. A. McDougall
Roxanne Hastie
Maya Goldstein
Andrew Tuttle
Stephen Tong
Anne Ammerdorffer
A. Metin Gülmezoglu
Joshua P. Vogel
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Chloroquin
Esomeprazole
Chloroquin
Metformin
Sulfasalazine
Pre-Eclampsia
Published in: BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-022-02582-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Blackwater fever and acute kidney injury in children hospitalized with an acute febrile illness: pathophysiology and prognostic significance

Healthy lifestyle counteracts the risk effect of genetic factors on incident gout: a large population-based longitudinal study

Global prevalence and burden of meal-related abdominal pain

Maternal blood pressure associates with placental DNA methylation both directly and through alterations in cell-type composition

Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors